Forefront Analytics LLC Has $78,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Forefront Analytics LLC grew its holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 206.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 64,065 shares of the biotechnology company’s stock after acquiring an additional 43,176 shares during the quarter. Forefront Analytics LLC owned 0.08% of CytomX Therapeutics worth $78,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of CTMX. Cubist Systematic Strategies LLC boosted its holdings in CytomX Therapeutics by 96.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 40,309 shares during the period. Sei Investments Co. bought a new stake in shares of CytomX Therapeutics in the second quarter valued at approximately $467,000. XTX Topco Ltd grew its position in CytomX Therapeutics by 382.6% during the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after buying an additional 48,033 shares in the last quarter. Acadian Asset Management LLC increased its stake in CytomX Therapeutics by 1.4% during the 2nd quarter. Acadian Asset Management LLC now owns 2,728,569 shares of the biotechnology company’s stock worth $3,324,000 after acquiring an additional 37,739 shares during the period. Finally, Candriam S.C.A. bought a new position in CytomX Therapeutics during the 2nd quarter worth $256,000. 67.77% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently issued reports on CTMX shares. HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, September 13th. StockNews.com cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, June 17th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $5.77.

CytomX Therapeutics Stock Performance

Shares of CTMX stock opened at $1.20 on Friday. CytomX Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $5.85. The stock’s fifty day moving average price is $1.24 and its two-hundred day moving average price is $1.67. The company has a market cap of $93.50 million, a PE ratio of 6.00 and a beta of 1.03.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $25.12 million during the quarter, compared to analyst estimates of $21.79 million. CytomX Therapeutics had a net margin of 9.27% and a negative return on equity of 27.44%. During the same period last year, the business earned ($0.02) earnings per share. On average, equities analysts predict that CytomX Therapeutics, Inc. will post -0.2 EPS for the current fiscal year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.